A Study of Ruxolitinib and Pembrolizumab in People With Lymphoma

Full Title

A Phase II Trial of JAK Inhibitor added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphomas and 9p Amplified Lymphomas

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Alison Moskowitz’s office at 646-608-3726.

Protocol
26-247
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Alison J. Moskowitz
Co-Investigators
Shamir Geller
Steven M. Horwitz
Diseases
Lymphoma
Lymphoma › Non-Hodgkin's Lymphoma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07283822
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description